Real-world antitumor activity of lenvatinib and pembrolizumab
| Variable | N (%) |
|---|---|
| Complete response | 3 (5.0) |
| Partial response | 26 (43.33) |
| ORR | 29 (48.33) |
| Stable disease | 23 (38.33) |
| Disease control rate | 52 (86.7) |
| Progressive disease | 8 (13.3) |
ORR: objective response rate